In March 2025, the American Society of Addiction Medicine (ASAM) released their updated guidelines regarding the tapering of benzodiazepines (BZDs). These guidelines were designed to provide evidence-based recommendations aimed at aiding clinicians in safely reducing BZD dependence in patients, all while minimizing withdrawal risks. The focus of these guidelines is on implementing safe tapering practices, delivering patient-centered care, and offering strategies to tackle the challenges that clinicians encounter when managing BZD discontinuation, especially in patients with long-term use or dependency.

This discussion will focus on the key points outlined in ASAM's Benzodiazepine Tapering guideline. While this summary provides a general overview of the main aspects, for a more comprehensive understanding, please refer to the pocket guide available here, or access the full guideline here.

Key Takeaways

General Principles of Benzodiazepine Tapering

The ASAM guidelines emphasize a gradual and individualized approach to BZD tapering. Abrupt discontinuation of benzodiazepines can precipitate severe withdrawal symptoms, including seizures, and significantly increase the risk of adverse outcomes. The tapering process must therefore be carefully planned to ensure both patient safety and comfort.

  • Gradual Reduction: It is recommended that tapering occur at a pace of 5-10% reduction in the current daily dose every 1-2 weeks, adjusting the pace based on the patient's tolerance, withdrawal symptoms, and clinical response. Faster reductions may be appropriate in certain cases, but they should be made with caution and close monitoring.
  • Personalization of Tapering: The tapering process should be personalized to each patient’s needs, considering their clinical profile, including comorbid conditions, history of substance use disorder, and the duration of benzodiazepine use. Some patients may require slower tapers, particularly those who have been on benzodiazepines for long periods or who are at higher risk for withdrawal complications.
  • Minimizing Withdrawal Symptoms: The goal of tapering is to minimize withdrawal symptoms while also addressing the underlying reasons for BZD use. Clinicians should be prepared to manage withdrawal symptoms and adjust the tapering schedule accordingly.

Transitioning to Longer-Acting Benzodiazepines

For patients using short-acting benzodiazepines (e.g., alprazolam, lorazepam), transitioning to a longer-acting benzodiazepine (e.g., diazepam, clonazepam) can make the tapering process more manageable. The longer half-life of these medications reduces the severity of withdrawal symptoms and provides a smoother transition.

  • Rationale for Transitioning: Longer-acting benzodiazepines, due to their pharmacokinetic properties, allow for more stable plasma drug levels, reducing the peaks and troughs associated with short-acting BZDs that can exacerbate withdrawal symptoms.
  • Dosing Considerations: When transitioning, clinicians should calculate an equivalent dose of a longer-acting BZD. While diazepam is commonly used for this purpose, the dose adjustment should take into account the specific drug properties, the patient’s response, and any existing comorbidities.

Monitoring and Adjusting the Tapering Process

Frequent Monitoring: Clinicians should closely monitor patients during the tapering process for any signs of withdrawal, including physical and psychological symptoms such as anxiety, agitation, tremors, and sleep disturbances. Regular follow-up visits should be scheduled to assess patient progress and make adjustments as needed.

  • Adjusting the Taper Rate: If significant withdrawal symptoms emerge or if the patient exhibits signs of distress, clinicians may need to slow down the tapering process or temporarily pause the reduction. In some cases, temporary stabilization at a particular dose may be necessary before further reductions are made.
  • Use of Symptom-Targeted Medications: In certain cases, adjunctive medications such as anticonvulsants, antidepressants, or beta-blockers may be prescribed to help alleviate withdrawal symptoms. These medications should be used cautiously and tailored to the patient's individual needs.

Special Populations

  • Older Adults: The guidelines highlight that older adults may be more vulnerable to the adverse effects of both benzodiazepines and withdrawal. Age-related changes in pharmacokinetics and increased sensitivity to sedating medications require clinicians to proceed with extra caution when tapering BZDs in this population.
  • Slower Tapering: In older patients, the tapering process should typically be slower, with a reduction of no more than 5% of the total dose every 1-2 weeks.
  • Comorbid Conditions: It is crucial to take into account the patient’s other medical conditions, such as liver dysfunction, which may affect the metabolism of benzodiazepines.
  • Patients with Substance Use Disorders (SUDs): Special consideration is required for patients with a history of substance use disorder. These patients may experience heightened withdrawal symptoms or psychological distress during tapering.
  • Dual Diagnosis Approach: A multidisciplinary approach involving addiction specialists, mental health professionals, and primary care providers is critical for managing these patients safely.

Patient-Centered Care and Shared Decision-Making

The ASAM guidelines emphasize the importance of involving patients in the decision-making process, ensuring they are informed about the risks and benefits of tapering and their role in managing their treatment.

  • Education and Communication: Educating patients about the risks of long-term benzodiazepine use, withdrawal symptoms, and the tapering process itself is critical to improving adherence and managing expectations. Patients should be made aware that tapering may take several months to complete.
  • Psychosocial Support: Supportive resources, including counseling or group therapy, may be beneficial in addressing underlying anxiety or insomnia and can help patients cope with the psychological aspects of tapering. Clinicians should offer or refer patients to appropriate psychosocial interventions, especially if underlying psychiatric disorders contribute to the patient’s initial need for benzodiazepines.
  • Shared Decision-Making: Engage patients in a collaborative approach, where their preferences and concerns are considered. This helps ensure that patients are not only compliant with the tapering plan but also more likely to succeed in the long term.

Considerations for Discontinuation of Benzodiazepines in High-Risk Situations

  • Severe Dependence: Patients with severe benzodiazepine dependence or those who experience significant withdrawal symptoms may need to be managed in a more controlled setting, such as inpatient or intensive outpatient care, where more intensive monitoring and intervention are available.
  • Co-occurring Disorders: Patients with psychiatric or medical comorbidities, such as depression, insomnia, or generalized anxiety disorder, require extra attention. These conditions should be addressed as part of the tapering process to help mitigate the potential for relapse or exacerbation of symptoms during the taper.

The 2025 ASAM Benzodiazepine Tapering Guideline provides recommendations to guide physicians in safely tapering benzodiazepines in patients. The core principles focus on a patient-centered, gradual, and individualized approach to reduce the risk of withdrawal and ensure patient comfort. Special attention is needed when treating older adults, patients with substance use disorders, and individuals with comorbidities. Clinicians should provide frequent monitoring, education, and psychosocial support to enhance the success of the tapering process. By adhering to these updated guidelines, physicians can help patients safely discontinue benzodiazepines, reduce the potential for withdrawal-related complications, and improve overall patient outcomes in the management of benzodiazepine dependence.


We hope you found this Guideline Spotlight informative. We look forward to hearing your thoughts and feedback as we continue to share valuable insights in our future spotlights. Thank you for being a valued member of our community!

Sign up for alerts and stay informed on the latest published guidelines and articles.

Copyright © 2025 Guideline Central, all rights reserved.